PDCD1 and neoplasm: It was expected that for patients receiving PF-07209960, differences in peripheral versus intratumoral activation of PD-1-expressing T cells could allow systemically administered PF-07209960 to reach levels required for tumor-specific T-cell proliferation and cytotoxicity and may not necessarily lead to systemic toxicity.